GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Future Medicine Co Ltd (XKRX:341170) » Definitions » Loans Receivable

Future Medicine Co (XKRX:341170) Loans Receivable : ₩0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Future Medicine Co Loans Receivable?

Future Medicine Co's Loans Receivable for the quarter that ended in Dec. 2024 was ₩0.00 Mil.


Future Medicine Co Loans Receivable Historical Data

The historical data trend for Future Medicine Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Future Medicine Co Loans Receivable Chart

Future Medicine Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Future Medicine Co Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Future Medicine Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Future Medicine Co Loans Receivable Related Terms

Thank you for viewing the detailed overview of Future Medicine Co's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Future Medicine Co Business Description

Traded in Other Exchanges
N/A
Address
54 changup-ro, 616, 2 Techno Valley Enterprise Growth Center, Gyeonggi-do, Siheung-dong, LH Pangyo-je, Seongnam-si, KOR, 13449
Future Medicine Co Ltd is a drug development company. It engages in the development of new drug candidates for anti-inflammatory/anti-fibrosis of non-alcoholic hepatitis (NASH) drugs, oral glaucoma treatments, and chronic kidney disease treatments, as well as targeted and Immuno cancer drugs.

Future Medicine Co Headlines

No Headlines